Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...
Knox Henderson | 3 days ago |

Rick Rule's holiday gifts to grow wealth

The average Canadian will spend C$1478 this holiday season with 43 per cent of the budget spent with online platforms Rule likes the idea of gifting precious metals and company shares as an alternative to traditional Christmas gifts “Philanthropy with a...
Coreena Robertson | December 4, 2024 |

Buzz on the Bullboards: Stocks making news as markets hit new highs

The past week has been eventful for North American stock markets, with the TSX and Dow Jones closing at fresh highs. However, equities in Toronto gave up some of their gains, reflecting a mixed sentiment among investors. Among the standout performers in Canada, three ...
Jonathon Brown | July 18, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Buzz on the Bullboards: Pulling gains out of volatile territory

As the global economy navigates uncertainties, investors have been watching the performance of key stock markets for insights into prevailing sentiment and economic health. Over the past week, the TSX and the trio of indices on Wall Street – the Dow Jones Industrial A...
Jonathon Brown | March 28, 2024 |

U.S. spot Bitcoin ETFs are live – what happens to Canada’s crypto ETFs?

By Shaed Hashimkhial The SEC’s endorsement of U.S. spot Bitcoin ETFs significantly influenced the cryptocurrency markets. Shortly after the announcement, we witnessed a substantial rally in Bitcoin, a notable increase in Ethereum’s...
Research | March 26, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

A recent PEA which demonstrates a very competitive uranium deposit

The following is a transcription of the above video, and The Market Online has edited it for clarity . Uranium has been making headlines with its supply and demand imbalance. Its price is bullish, and the trend has been predicted to continue well into the year. ...
Brieanna McCutcheon | March 19, 2024 |

Buzz on the Bullboards: Hot stocks from copper to Bombardier and AI

These leap-days are a rare treat. Not only is it an extra day to hold off on rent/mortgage payments, but an extra day to take stock of February’s wild ride. Last week, we saw the TSX hit a 22-month high while major U.S. indices also had their best pe...
Jonathon Brown | February 29, 2024 |

Buzz on the Bullboards: Recognizing the best of the best

Investors don’t prosper on potential. Investors prosper on returns. These days, plenty of companies are able to reward return-starved investors with a strong stock performance. However, many still look to short-term trading or chasing momentum for a qu...
Jonathon Brown | February 22, 2024 |
1 2 3 4 5 6 7 8 9 10 ...